Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Abstract: The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.

Abstract: The invention concerns a system for delivering a voltage to at least one power domain (2.11-2. nz) comprising at least one component, each power domain functioning according to at least two operating points, each operating point defining a required supply voltage, the required supply voltages of the operating points of a given power domain being distinct in pairs. The system comprises at least a first and a second power supply units (1.10-1.n0), each supply unit being adapted to deliver a controllable supply voltage and the at least one power domain comprises at least one first power domain (2.1 x; 2.2y; 2.nz), which is arranged to be alternatively connected to the first or to the second power supply unit.

Abstract: Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus.

Abstract: The present invention relates to a novel pharmaceutical composition comprising oxytocin and/or one or more fragment(s) and/or variant(s) thereof and at least one non-ionic cellulose ether, such as hydroxypropylmethylcellulose, said pharmaceutical composition having a low pH. The present pharmaceutical composition has been shown to provide an exceptionally suitable environment for oxytocin, as the stability thereof has increased significantly as compared to previous compositions with this molecule. The pharmaceutical composition according to the invention can be used for medical purposes, such as in the treatment of climacteric disorders.

Abstract: The present invention takes advantage of a phase correlation process at a receiver, for example the plurality of different clock phases that are provided for ascertaining the most favourable phase for burst reception in a digital signalling link, and uses this phase correlation information for a different purpose. For example, the plurality of different clock phases are used to provide an indication of the quality of the received signal. The quality of the received signal can then be used to adapt one or more parameters in the digital plurality of different clock phases signalling link, to save power when desired.

Abstract: A lipid layer forming composition for topical treatment of psoriasis comprises volatile silicone oil, polar lipid, C2-C4 aliphatic alcohol, and a pharmacologically effective amount of an agent for the treatment of psoriasis, wherein the silicone oil has a boiling point above 180° C., in particular above 200° C. The composition does not comprise polymer silicone. Also disclosed are corresponding methods of treatment and of manufacture of the composition.

Abstract: The present invention relates to a water-free pharmaceutical composition comprising one or more local anaesthetics in base form and which is suitable for topical administration. The composition further comprises a lipid vehicle comprising long-chain triglycerides (LCT) and at least 10% by weight of medium-chain monoglycerides (MCM) selected so the composition has an at least semi-solid appearance at the body temperature at the site of administration. The invention further relates to methods of producing and sterilizing the compositions.

Abstract: There is provided homogeneous pharmaceutical compositions for the treatment of, for example, rhinitis, asthma and/or chronic obstructive pulmonary disease comprising a corticosteroid and an antihistamine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier.

Abstract: A method in a communication device and a communication device (100) for adapting a transmission of data are provided. The transmission is transferred from a first chip (110) to a second chip (120) over a chip-to-chip interface (104, 304). The chip-to-chip-interface comprises a wired connection between the first chip and the second chip which is comprised in the communication device. The communication device receives (201) the radio signal (330), comprising the transmission of data from another communication device. The communication device determines (202), from the 204 received radio signal (330), modulation and coding information, which is used for determining (203) a channel quality. Further, the communication device (100) adapts (204) the transmission of data based on the determined channel quality of the received radio signal (330) in such way that at least the determined channel quality is obtained when transferring (205) the transmission of data over the chip-to-chip interface to the second chip.

Abstract: A method in a communication device (100) and a communication device (100) for utilizing a first power mode and a second power mode of a digital interface (130, 330) between a first chip (110, 310) and a second chip (120, 320) are provided. When in the second power mode, the digital interface (130, 330) receives a data signal in a first time slot. The data signal comprises a control channel and a data channel. When the digital interface (130,330) enters the first power mode, the communication device (100) will determine a first point in time based on information comprised in the control channel. Furthermore, the communication device (100) determines a second point in time based on amount of data which is carried by the data channel at the first point in time. At the second point in time, the digital interface (130, 330) enters the second power mode and the data signal is transferred.

Abstract: A fluid carrier comprises first and second substantially immiscible liquids. The first liquid is an open-chain silicone oil of the formula [(CH3)3Si—O]—[(CH2)2Si—O]n—[Si(CH3)3]. The second liquid is a polar lipid material. The first and second liquids are capable of forming an unstable dispersion. The unstable dispersion can be stabilized by adding a powderous solid insoluble in the liquids. The powderous solid is selected from pharmacologically active agent, pharmaceutical excipient, and their mixtures. The stabilized dispersion is of a creamy or ointment-like or mouldable form, and can be filled into capsules or moulded into tablets so as to be fit for peroral administration.

Abstract: A multi-pivot pin system has a hinge assembly having a plurality of housings formed within the hinge assembly. A channel is formed through each housing wherein an outer diameter center-line of the hinge assembly is off-set from a center-line of an inner diameter of the channel. A rotating device is positioned in each channel.

Abstract: The invention provides a process for removing mercaptans from a gas stream comprising natural gas or inert gas and mercaptans, the process comprising the steps of: (a) contacting a first gas stream comprising natural gas or inert gas and mercaptans with a hydrodesulphurization catalyst in the presence of hydrogen in a hydrodesulphurization unit to obtain a second gas stream comprising natural gas or inert gas, which is depleted of mercaptans and enriched in H2S; (b) removing H2S from the second gas stream comprising natural gas or inert gas in a H2S removal unit to obtain a purified gas stream comprising natural gas or inert gas, which is depleted of mercaptans.

Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Abstract: The invention provides a process for the regeneration of at least one adsorbent bed, comprising at least the steps of: (a) contacting a first adsorbent bed (B1) with a gaseous stream (10) such that at least a portion of adsorbed species in said first adsorbent bed (B1) are released; (b) cooling a second adsorbent bed (B2); wherein a bypass (20) is provided around the second adsorbent bed (B2) and the gaseous stream (10), before contact with the first adsorbent bed (B1), is directed to at least one of (i) the second adsorbent bed (B2), and (ii) the bypass (20) around the second adsorbent bed (B2), wherein the proportion of gaseous stream (10) flowing through the bypass (20) is controlled.

Abstract: A medical monitoring unit for continuously monitoring a glucose value and a lactate value is provided. The monitoring unit comprises: a display unit, a first unit adapted to: receive a glucose/lactate/pyruvate signal based on a measured glucose/lactate/pyruvate value, transform the glucose signal into a graphically displayable glucose/lactate/pyruvate signal, and transmit the graphically displayable glucose/lactate/pyruvate signal to the display unit of the monitoring unit, and a second unit adapted to: receive a glucose/lactate/pyruvate signal based on a measured glucose/lactate/pyruvate value, transform the glucose/lactate/pyruvate signal into a graphically displayable glucose/lactate/pyruvate signal, and transmit the graphically displayable glucose/lactate/pyruvate signal to the display unit of the monitoring unit.

Abstract: There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.